Overview of the Supreme Court’s review of skinny labeling in Amarin Inc. v. Hikma Pharm. USA, Inc., and its implications for generic drug makers, marketing, and inducement liability.
| less than a minute read
The Skinny Labeling Saga Continues

/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-02-20-21-00-36-649-6998cb749e22a2a4c3b916ca.jpg)

/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-02-20-20-58-30-584-6998caf69e22a2a4c3b91338.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-02-19-21-53-49-178-6997866d2a5da1507878fef3.jpg)